Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Dives Back Into Opioid Reviews Under New Division Leadership

Jan 06 2020

• By Michael McCaughan

People running from dangerous pills

Related Content

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

Aug 12 2019

FDA Panel Rejects Intellipharmaceutics' Opioid For Missing Data, Blue Dye Safety Concern

Jul 27 2017

Time To Spare? US FDA “Opioid-Sparing” Guidance May Take Longer Than Expected

Dec 18 2018

Related Companies

Nektar Therapeutics

Esteve Pharmaceuticals, S.A.

Pfizer Inc.

Intellipharmaceutics International Inc.

DURECT Corporation

Pacira BioSciences, Inc.

Additional Topics

United States Advisory Committees Drug Approval Standards Drug Review Drug Safety Regulation Leadership FDA Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.